JP2005503336A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005503336A5 JP2005503336A5 JP2002577862A JP2002577862A JP2005503336A5 JP 2005503336 A5 JP2005503336 A5 JP 2005503336A5 JP 2002577862 A JP2002577862 A JP 2002577862A JP 2002577862 A JP2002577862 A JP 2002577862A JP 2005503336 A5 JP2005503336 A5 JP 2005503336A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- polypeptide
- devg4
- devg22
- devg20
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 39
- 102000004196 processed proteins & peptides Human genes 0.000 claims 35
- 108020004707 nucleic acids Proteins 0.000 claims 34
- 102000039446 nucleic acids Human genes 0.000 claims 34
- 150000007523 nucleic acids Chemical class 0.000 claims 34
- 229920001184 polypeptide Polymers 0.000 claims 34
- 239000000203 mixture Substances 0.000 claims 16
- 239000012634 fragment Substances 0.000 claims 11
- 238000000034 method Methods 0.000 claims 10
- 239000003795 chemical substances by application Substances 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 5
- 208000029078 coronary artery disease Diseases 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 108091023037 Aptamer Proteins 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 108010006533 ATP-Binding Cassette Transporters Proteins 0.000 claims 3
- 102000005416 ATP-Binding Cassette Transporters Human genes 0.000 claims 3
- 206010003210 Arteriosclerosis Diseases 0.000 claims 3
- 206010006895 Cachexia Diseases 0.000 claims 3
- 208000032928 Dyslipidaemia Diseases 0.000 claims 3
- 208000030814 Eating disease Diseases 0.000 claims 3
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 3
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 3
- 206010020772 Hypertension Diseases 0.000 claims 3
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 3
- 208000008589 Obesity Diseases 0.000 claims 3
- 102000006010 Protein Disulfide-Isomerase Human genes 0.000 claims 3
- 208000010399 Wasting Syndrome Diseases 0.000 claims 3
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 3
- 201000001883 cholelithiasis Diseases 0.000 claims 3
- 230000000295 complement effect Effects 0.000 claims 3
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 235000014632 disordered eating Nutrition 0.000 claims 3
- 230000004064 dysfunction Effects 0.000 claims 3
- 235000020824 obesity Nutrition 0.000 claims 3
- 210000000056 organ Anatomy 0.000 claims 3
- 201000008482 osteoarthritis Diseases 0.000 claims 3
- 201000002859 sleep apnea Diseases 0.000 claims 3
- 239000013598 vector Substances 0.000 claims 3
- 108020004414 DNA Proteins 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 108091034117 Oligonucleotide Proteins 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 239000000074 antisense oligonucleotide Substances 0.000 claims 2
- 238000012230 antisense oligonucleotides Methods 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000004927 fusion Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000004060 metabolic process Effects 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 230000007935 neutral effect Effects 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 108020003519 protein disulfide isomerase Proteins 0.000 claims 2
- 230000009892 regulation of energy homeostasis Effects 0.000 claims 2
- 230000001850 reproductive effect Effects 0.000 claims 2
- 238000012216 screening Methods 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 108700014181 ABC-type protein transporter activity proteins Proteins 0.000 claims 1
- 102000053602 DNA Human genes 0.000 claims 1
- -1 For example Proteins 0.000 claims 1
- 101000986629 Homo sapiens ATP-binding cassette sub-family C member 4 Proteins 0.000 claims 1
- 101001072202 Homo sapiens Protein disulfide-isomerase Proteins 0.000 claims 1
- 108010060231 Insect Proteins Proteins 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 239000002299 complementary DNA Substances 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037765 diseases and disorders Diseases 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 102000044501 human ABCC4 Human genes 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 238000009396 hybridization Methods 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 230000005994 pancreas dysfunction Effects 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
- 201000011453 reproductive organ cancer Diseases 0.000 claims 1
- 208000015608 reproductive system cancer Diseases 0.000 claims 1
- 239000000523 sample Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 230000009261 transgenic effect Effects 0.000 claims 1
- 238000012795 verification Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01108315 | 2001-04-02 | ||
| EP01113419 | 2001-06-01 | ||
| PCT/EP2002/003540 WO2002079238A2 (en) | 2001-04-02 | 2002-03-28 | Protein disulfide isomerase and abc transporter homologous proteins involved in the regulation of energy homeostasis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005503336A JP2005503336A (ja) | 2005-02-03 |
| JP2005503336A5 true JP2005503336A5 (enExample) | 2005-12-22 |
Family
ID=26076527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002577862A Pending JP2005503336A (ja) | 2001-04-02 | 2002-03-28 | エネルギー恒常性の調節に関与する、タンパク質ジスルフィド異性化酵素およびａｂｃ輸送体の相同性タンパク質 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US7211563B2 (enExample) |
| EP (1) | EP1373495B1 (enExample) |
| JP (1) | JP2005503336A (enExample) |
| AT (1) | ATE422540T1 (enExample) |
| DE (1) | DE60231110D1 (enExample) |
| WO (1) | WO2002079238A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004035082A2 (en) * | 2002-10-14 | 2004-04-29 | DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung | Proteins involved in the regulation of energy homeostasis |
| WO2005001092A2 (en) * | 2003-05-20 | 2005-01-06 | Wyeth | Compositions and methods for diagnosing and treating cancers |
| WO2006028655A2 (en) * | 2004-08-13 | 2006-03-16 | Millennium Pharmaceuticals, Inc. | Genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer |
| WO2012155070A1 (en) * | 2011-05-12 | 2012-11-15 | Salk Institute For Biological Studies | Modulation of lipid homeostatis, methods and compositions related thereto |
| JP7170542B2 (ja) * | 2016-05-10 | 2022-11-14 | メディミューン，エルエルシー | タンパク質ジスルフィド結合の還元の防止 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0896964B1 (de) * | 1997-07-24 | 2006-03-08 | Ciba SC Holding AG | Perylenhydrazidimide als Carbonylderivatisierungsreagenzien |
| WO2000005368A1 (en) * | 1998-07-20 | 2000-02-03 | Incyte Pharmaceuticals, Inc. | Human calcium regulatory proteins |
| US6759238B1 (en) * | 1999-03-31 | 2004-07-06 | St. Jude Children's Research Hospital | Multidrug resistance associated proteins and uses thereof |
| US6753314B1 (en) * | 1999-04-01 | 2004-06-22 | Curagen Corporation | Protein-protein complexes and methods of using same |
| AU2001289864A1 (en) * | 2000-09-08 | 2002-03-22 | Bayer Aktiengesellschaft | Regulation of human protein disulfide isomerase-like enzyme |
| WO2003072827A1 (en) * | 2001-10-31 | 2003-09-04 | Children's Hospital Medical Center | Method for diagnosis and treatment of rheumatoid arthritis |
-
2002
- 2002-03-28 JP JP2002577862A patent/JP2005503336A/ja active Pending
- 2002-03-28 AT AT02757730T patent/ATE422540T1/de not_active IP Right Cessation
- 2002-03-28 US US10/473,696 patent/US7211563B2/en not_active Expired - Fee Related
- 2002-03-28 DE DE60231110T patent/DE60231110D1/de not_active Expired - Lifetime
- 2002-03-28 WO PCT/EP2002/003540 patent/WO2002079238A2/en not_active Ceased
- 2002-03-28 EP EP02757730A patent/EP1373495B1/en not_active Expired - Lifetime
-
2006
- 2006-12-05 US US11/567,064 patent/US20080075713A1/en not_active Abandoned
- 2006-12-05 US US11/567,079 patent/US7404952B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Holcomb et al. | FIZZ1, a novel cysteine‐rich secreted protein associated with pulmonary inflammation, defines a new gene family | |
| Introna et al. | Cloning of mouse ptx3, a new member of the pentraxin gene family expressed at extrahepatic sites | |
| AU2005265150B2 (en) | C-MET kinase binding proteins | |
| JP6704358B2 (ja) | 代謝障害を治療するための組成物および使用方法 | |
| CN109069636A (zh) | 用于调节体重的组合物和方法 | |
| Boughton et al. | Can neuropeptides treat obesity? A review of neuropeptides and their potential role in the treatment of obesity | |
| JP2008503216A5 (enExample) | ||
| JP2002505843A (ja) | システインリッチなレセプターであるｔｒａｉｎ | |
| CN105601748A (zh) | 用于代谢病症和疾病治疗的组合物、应用和方法 | |
| JP2006523440A (ja) | 若年性ヘモクロマトーシス遺伝子（ｈｆｅ２ａ）、その発現産物および使用法 | |
| Denton et al. | A β-peptide agonist of the GLP-1 receptor, a class B GPCR | |
| US7820790B2 (en) | IL-6 binding proteins | |
| AU2016252426A1 (en) | Fibroblast growth factor (FGF) 1 mutants and methods of use to reduce blood glucose | |
| WO2015061351A1 (en) | Chimeric fibroblast growth factor (fgf) 2/fgf1 peptides and methods of use | |
| Kanematsu-Yamaki et al. | Potent body weight-lowering effect of a neuromedin U receptor 2-selective PEGylated peptide | |
| JP2005519608A5 (enExample) | ||
| JP2009501517A (ja) | Ｉｌ−６結合タンパク質 | |
| CN106456700B (zh) | 糖尿病治疗和预防的新靶标 | |
| JP2005503336A5 (enExample) | ||
| CN1159585C (zh) | 检测瘦素的方法 | |
| Ek et al. | An anti-sortilin affibody-peptide fusion inhibits sortilin-mediated progranulin degradation | |
| Poole et al. | A C-terminal cysteine residue is required for peptide-based inhibition of the NGF/TrkA interaction at nM concentrations: implications for peptide-based analgesics | |
| WO2009023125A1 (en) | Neuronostatin and its uses | |
| JP2007519894A (ja) | 標的としてのカドヘリンの使用 | |
| JP2005512509A5 (enExample) |